Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00312663 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America
A Phase 1 study of Plasmodium Falciparum Malaria, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00312663 is a Phase 1 study of Plasmodium Falciparum Malaria that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00312663, a Phase 1 study of Plasmodium Falciparum Malaria, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase I/II Trial of a Malaria Vaccine, FMP011/AS01B, in Adults Living in the United States of America.
Conditions Studied
Interventions
- BIOLOGICAL Falciparum Malaria Protein 11 with AS01B adjuvant.
Study Locations (1)
Maryland
- Walter Reed Army Institute of Research - Silver Spring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2006-04 |
| Est. Completion | 2007-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00312663
The ClinicalTrials.gov registry entry for NCT00312663 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plasmodium Falciparum Malaria appearing as the primary indexed condition, and to 1 intervention - of which Falciparum Malaria Protein 11 with AS01B adjuvant. is the first listed.
NCT00312663 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00312663 about?
NCT00312663 is a clinical study titled "Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America". Phase I/II Trial of a Malaria Vaccine, FMP011/AS01B, in Adults Living in the United States of America.
What is the current status of trial NCT00312663?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2006-04. Estimated completion is 2007-04.
What conditions does trial NCT00312663 study?
This clinical trial studies the following conditions: Plasmodium Falciparum Malaria.
What interventions are being tested in trial NCT00312663?
The interventions under investigation include: Falciparum Malaria Protein 11 with AS01B adjuvant. (BIOLOGICAL).
Who is sponsoring clinical trial NCT00312663?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00312663 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plasmodium Falciparum Malaria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.